Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 6/2016

Open Access 01-06-2016 | Clinical Investigation

PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response

Authors: Kathryn J. Fowler, Nichole M. Maughan, Richard Laforest, Nael E. Saad, Akash Sharma, Jeffrey Olsen, Christina K. Speirs, Parag J. Parikh

Published in: CardioVascular and Interventional Radiology | Issue 6/2016

Login to get access

Abstract

Purpose

The purpose of our study is to determine if there is a relationship between dose deposition measured by PET/MRI and individual lesion response to yttrium-90 (90Y) microsphere radioembolization.

Materials and Methods

26 patients undergoing lobar treatment with 90Y microspheres underwent PET/MRI within 66 h of treatment and had follow-up imaging available. Adequate visualization of tumor was available in 24 patients, and contours were drawn on simultaneously acquired PET/MRI data. Dose volume histograms (DVHs) were extracted from dose maps, which were generated using a voxelized dose kernel. Similar contours to capture dimensional and volumetric change of tumors were drawn on follow-up imaging. Response was analyzed using both RECIST and volumetric RECIST (vRECIST) criteria.

Results

A total of 8 hepatocellular carcinoma (HCC), 4 neuroendocrine tumor (NET), 9 colorectal metastases (CRC) patients, and 3 patients with other metastatic disease met inclusion criteria. Average dose was useful in predicting response between responders and non-responders for all lesion types and for CRC lesions alone using both response criteria (p < 0.05). D70 (minimum dose to 70 % of volume) was also useful in predicting response when using vRECIST. No significant trend was seen in the other tumor types. For CRC lesions, an average dose of 29.8 Gy offered 76.9 % sensitivity and 75.9 % specificity for response.

Conclusions

PET/MRI of 90Y microsphere distribution showed significantly higher DVH values for responders than non-responders in patients with CRC. DVH analysis of 90Y microsphere distribution following treatment may be an important predictor of response and could be used to guide future adaptive therapy trials.
Literature
1.
Burton M, Gray B, Kelleher D, et al. Selective internal radiation therapy: validation of intraoperative dosimetry. Radiology. 1990;175:253–5.CrossRefPubMed
2.
Gray B, Burton M, Kelleher D, et al. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol. 1989;42:192–6.CrossRefPubMed
3.
Burton M, Gray B, Klemp P, et al. Selective internal radiation therapy: distribution of radiation in the liver. Eur J Cancer Clin Oncol. 1989;25:1487–91.CrossRefPubMed
4.
Kennedy A, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–63.CrossRefPubMed
5.
Ackerman NB, Lien W, Kondi ES, et al. The blood supply of experimental liver metastases. I: the distribution of hepatic artery and portal vein blood to “small and “large tumors. Surgery. 1970;66:1067–72.
6.
Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (RE-BOC). Int J Radiat Oncol Biol Phys. 2007;68:13–23.CrossRefPubMed
7.
Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol. 2012;35(1):91–9.CrossRefPubMed
8.
Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10:S107–10.CrossRefPubMed
9.
Furuse J, Ishii H, Nagase M, et al. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20(10):1512–8.CrossRefPubMed
10.
Lewandowski RJ, Mulcahy M, Kulik L, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010;255(3):955–65.CrossRefPubMedPubMedCentral
11.
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64.CrossRefPubMed
12.
Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.CrossRefPubMed
13.
Carretero C, Munoz-Navas M, Betes R, et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol. 2007;102:1216–20.CrossRefPubMed
14.
Naymagon S, Warner R, Patel K, et al. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig Dis Sci. 2010;55:2450–8.CrossRefPubMed
15.
Leung T, Lau W, Ho S, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90 yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–24.CrossRefPubMed
16.
Vouch M, Salem R, Miller FH, Lemort M, Vanderlinden B, De Becker D, Hendlisz A, Flamen P. Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. Clin Imaging. 2015;39(3):453–62.
17.
Vouche M, Salem R, Leandowski RJ, Miller FH. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? Abdom Imaging. 2014;295:1–10.
18.
Kokabi N, Galt J, Xing M, et al. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. J Vasc Interv Radiol. 2014;25(2):277–87.CrossRefPubMed
19.
Sarfaraz M, Kennedy A, Lodge M, Li X, Wu X, Yu C. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys. 2004;31(9):2449–53.CrossRefPubMed
20.
Minarik D. Sjogreen Gleisner K, Ljungberg M. Evaluation of quantitative 90Y SPECT based on experimental phantom studies. Phys Med Biol. 2008;53(20):5689–703.CrossRefPubMed
21.
Rault E, Staelens S, Van Holen R, et al. Fast simulation of yttrium-90 bremsstrahlung photons with GATE. Med Phys. 2010;37(6):2943–50.CrossRefPubMed
22.
Carlier T, Eugene T, Bodet-Milin C, et al. Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI. 2013;3(1):11.CrossRef
23.
Gates V, Esmail A, Marshall K, Spies S, Salem R. Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med. 2011;52(1):72–6.CrossRefPubMed
24.
Lhommel R, Goffette P, Van den Eynde M, et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging. 2009;36(10):1696.CrossRefPubMed
25.
Padia SA, Alessio A, Kwan S, et al. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol. 2013;24(8):1147–53.CrossRefPubMed
26.
Kao YH, Steinberg J, Tay Y, et al. Post-radioembolization yttrium-90 PET/CT-part 1: diagnostic reporting. EJNMMI Res. 2013;25(3):56.CrossRef
27.
Kao YH, Steinberg J, Tay Y, et al. Post-radioembolization yttrium-90 PET/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res. 2013;25(3):57.CrossRef
28.
Zade A, Rangarajan V, Purandare N, et al. 90Y microsphere therapy:dose 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging? Nucl Med Commun. 2013;34(11):1090–6.CrossRefPubMed
29.
Selwyn RG, Avila-Rodriguez M, Converse A. 18F-labeled resin microspheres as surrogates for 90Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study. Phys Med Biol. 2007;52:7397–408.CrossRefPubMed
30.
Lea W, Tapp K, Tann M, et al. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with Yttrium-90 in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:1595–603.CrossRefPubMed
31.
Ng SC, Lee VH, Law MW, et al. Patient dosimetry for 90Y selective internal radiation treatment based on 90Y PET imaging. J Appl Clin Med Phys. 2013;14(5):212–21.PubMed
32.
Delso G, Furst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52(12):1914–22.CrossRefPubMed
33.
Maughan NM, Eldib M, Knesaurek K, Faul D, Parikh PJ, Fayad ZA, Laforest R. Phantom study to determine optimal PET reconstruction parameters for PET/MR imaging of Y-90 microspheres following radioembolization. Biomedical Physics and Engineering Express 2015 (in preparation).
34.
Bolch W, Bouchet L, Robertson J, et al. MIRD pamphlet No 17: the dosimetry of nonuniform activity distributions—radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. JNM. 1999;40(1):11S–36S.PubMed
35.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
36.
D’Arienzo M, Chiaramida P, Chiacchiararelli L, et al. 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun. 2012;33(6):633–40.CrossRefPubMed
37.
Gupta A, Gill A, Shrikanthan S, Srinivas S. Nontargeted y-90 microsphere radioembolization to duodenum visualized on Y-90 PET/CT and Bremsstrahlung SPECT/CT. Clin Nucl Med. 2012;37(1):98–9.CrossRefPubMed
38.
Elschot M, Vermolen B, Lam M, et al. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 distribution after liver radioembolization. PLoS ONE. 2013;8(2):e55742.CrossRefPubMedPubMedCentral
39.
Tacher V, Lin M, Duran R, et al. Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology. 2015;1:142951.
40.
41.
42.
Chang T, Bourgeois A, Balius A, et al. Treatment modification of yttrium-90 radioembolization based on quantitative positron emission tomography/CT imaging. J Vasc Interv Radiol. 2013;24(3):333–7.CrossRefPubMed
43.
Willowson KP, Tapner M. QUEST Investigator Team, Bailey DL. A multicenter comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: the QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42(8):1202–22.CrossRefPubMedPubMedCentral
44.
Metadata
Title
PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response
Authors
Kathryn J. Fowler
Nichole M. Maughan
Richard Laforest
Nael E. Saad
Akash Sharma
Jeffrey Olsen
Christina K. Speirs
Parag J. Parikh
Publication date
01-06-2016
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 6/2016
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-015-1285-y

Other articles of this Issue 6/2016

CardioVascular and Interventional Radiology 6/2016 Go to the issue

Clinical Investigation

Long-Term Efficacy of Percutaneous Internal Plastic Stent Placement for Non-anastomotic Biliary Stenosis After Liver Transplantation

Clinical Investigation

Change in Imaging Findings on Angiography-Assisted CT During Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Case Report

Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis

Letter to the Editor

Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?

Technical Note

Transjugular Intrahepatic Portosystemic Shunt Flow Reduction with Adjustable Polytetrafluoroethylene-Covered Balloon-Expandable Stents Using the “Sheath Control” Technique

Letter to the Editor

Reply: Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?